Midsize Plans Struggle to Pay for Cell, Gene Therapies, Execs Say
-
Jun 13, 2024
It's no secret that health plans are concerned that they may not be able to afford gene and cell therapies with new or anticipated approvals. With expensive launches on the horizon, plans are searching for payment models that can grant patients access to lifesaving or life-changing therapies without blowing budgets.
Those concerns are particularly acute for smaller, regional health insurers and employer plan sponsors. Those payers may have tight balance sheets and lack the pricing advantages that national insurers can leverage in negotiations with manufacturers. Midsize plan executives say their organizations are figuring out what to do as they go along.
Read more
© 2024 MMIT
Related Posts
-
![]()
Dec 14
Bluebird, Vertex Gene Therapies May Answer $1m Question: Can Competition Reduce Rx Prices?
Read more -
![]()
Apr 25
ICER President, Gene Therapy Report Tackle Tough Cost-Control Questions
Read more -
![]()
Feb 08
Cell and Gene Therapies, Biosimilars, Medical Benefit Drugs Are Areas to Watch Moving Forward
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.